Divergent effects of retinoids on pancreatic and liver carcinogenesis in azaserine-treated rats.
Chemoprevention by synthetic retinoids of the progression of carcinomas of the pancreas induced in rats by azaserine was evaluated. Lewis rats were given five weekly injections of azaserine, 30 mg/kg, while being fed a chow diet. Two weeks after completion of carcinogen treatment, groups of rats were fed the chow diet supplemented with four different retinoids at the level of 0.5 to 2 mmol/kg of diet for 1 year. The incidence of pancreatic and other neoplasms was determined by autopsy and histological study. The incidence of localized pancreatic carcinoma among male and female non-retinoid-treated controls was 25 and 17%, respectively. No invasive or metastatic carcinomas were found in the control group. The combined incidence of localized and invasive pancreatic carcinomas among male and female rats treated with retinoids was: N-(4-pivaloyloxyphenyl)retinamide, 4 and 0%; N-(2-hydroxypropyl)retinamide, 14 and 6%; N-(3-hydroxypropyl)retinamide, 16 and 4%; and N-(2,3-dihydroxypropyl)retinamide, 12 and 6%. High- and low-dose groups are combined in this summary of data. Thus, there was a trend towards fewer pancreatic carcinomas among all retinoid-treated groups. The reduction in incidence was significant in both male and female rat groups given N-(4-pivaloyloxyphenyl)retinamide and N-(2,3-dihydroxypropyl)retinamide. The principal evidence of retinoid toxicity was growth failure, which was most severe in animals treated with N-(4-pivaloyloxyphenyl)retinamide, and testicular atrophy, which was most severe among male animals treated with N-(3-hydroxypropyl)retinamide. Among the females, groups treated with three of the four retinoids showed a dose-related increase in incidence of hepatocellular carcinomas. Since the retinoids were fed after the completion of exposure to the carcinogen, the effects on both pancreatic and liver carcinogenesis were exerted during the postinitiation phase of carcinogenesis.
D000818:Animals; D001284:Atrophy; D001377:Azaserine; D001835:Body Weight / Q000187:drug effects; D003043:Cocarcinogenesis; D004032:Diet; D005260:Female; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D051381:Rats; D011917:Rats, Inbred Lew; D012737:Sex Factors; D013737:Testis / Q000187:drug effects / Q000473:pathology; D014801:Vitamin A / Q000031:analogs & derivatives*
D014801:Vitamin A; D001377:Azaserine